Clinical Trials Logo

Clinical Trial Summary

Over-resuscitation including fluid overload has been associated with increased morbidity (prolonged duration of organ failure) and mortality in septic shock. "One-size-fits-all" resuscitation strategies may increase septic shock mortality. However, clinical studies on individualized resuscitation are lacking. Hemodynamic phenotyping may allow to individualize septic shock resuscitation. The ANDROMEDA-SHOCK trial found that a simple clinical and bedside CRT-targeted resuscitation reduces organ dysfunction and 28-day mortality in septic shock. The current study will examine the hypothesis that a CRT-targeted resuscitation based on hemodynamic phenotyping considering within an decision tree usual bedside clinical parameters such as pulse pressure, diastolic blood pressure, fluid responsiveness and cardiac performance can further decrease mortality in septic shock as compared to usual care.


Clinical Trial Description

Septic shock is associated with a high mortality risk related to progressive tissue hypoperfusion.However, despite extensive research on the best monitoring and resuscitation strategies, many uncertainties remain. Over-resuscitation, particularly when inducing fluid overload, might contribute to a worse outcome. Fluid overload more likely occurs when fluids are administered to fluid unresponsive patients, but also when inappropriate resuscitation goals are pursued, or a "one-size-fit all" strategy is followed. From a hemodynamic point of view, several pathogenic mechanisms determine a progressive circulatory dysfunction While loss of vascular tone and relative hypovolemia predominate in early phases, more complex mechanisms such as endothelial and microcirculatory dysfunction, progressive vasoplegia, and myocardial dysfunction may be involved later. In effect, from a clinical point of view, many patients despite been fluid loaded in pre-intensive care unit settings, are still evidently hypovolemic and benefit from further administration of fluid boluses. Others, however, present very low diastolic arterial pressures reflecting profound vasoplegia, and recent data suggest that these patients may benefit from early norepinephrine instead of fluids[; on the contrary, administering fluids may fail to correct vascular tone and increase the risk of fluid overload[2]. In addition, a recent echocardiography-based study confirms that a relevant myocardial dysfunction is present in a significant number of patients, and that several cardiovascular phenotypes with a potentially different therapeutic approach may be recognized[8]. Unfortunately, despite the availability of most of the parameters at the bedside and research efforts, no universally applicable clinical phenotyping method for septic shock patients has been translated to usual practice. This is particularly problematic since chocardiography is not immediately available in the majority of centers worldwide, and therefore initial decisions on fluid resuscitation are usually based on clinical grounds and tend to follow the one-size-fits-all principle, leading to the risk of fluid overload. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06062303
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Olfa MD Hamzaoui, PhD
Phone 0033310736973
Email ohamzaoui@chu-reims.fr
Status Recruiting
Phase N/A
Start date February 6, 2024
Completion date May 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03592693 - Vitamin C, Hydrocortisone and Thiamine for Septic Shock Phase 2
Terminated NCT01639664 - COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2 N/A
Withdrawn NCT01601938 - Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients Phase 2
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00000574 - Ibuprofen in Sepsis Study Phase 3
Recruiting NCT04910841 - Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine N/A
Active, not recruiting NCT04079829 - Postoperative Respiratory Abnormalities
Recruiting NCT04569942 - Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis Phase 3
Recruiting NCT04934943 - "Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
Completed NCT01310790 - Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock Phase 4
Completed NCT00241228 - Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care) N/A
Completed NCT00046072 - A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis Phase 2
Withdrawn NCT03122678 - Thiamine Supplementation in Patients With Septic Shock Phase 1
Recruiting NCT06155812 - Multimodal Vasopressor Strategy in Septic Shock Phase 2/Phase 3
Completed NCT04178148 - Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock N/A
Completed NCT01453270 - Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial N/A
Recruiting NCT04576819 - Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
Active, not recruiting NCT04055909 - Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock Phase 2
Suspended NCT03193164 - Neuromuscular Electrical Stimulation and Septic Shock N/A
Completed NCT04647552 - Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock